AbbVie Announces Positive Topline Results from Phase 2 LUMIN

/PRNewswire/ -- AbbVie (NYSE: ABBV) announced today topline results from the single-arm Phase 2 LUMINOSITY trial evaluating telisotuzumab-vedotin (Teliso-V) in...

Related Keywords

Colorado , United States , United Kingdom , Manchester , Taiwan , Japan , Taiwanese , Telisotuzumab Vedotin Teliso , Ross Camidge , Roopal Thakkar , Regulatory Agency , Facebook , Cancer Research United Kingdom , Exchange Commission , Linkedin , University Of Colorado Cancer Center , National Cancer Institute , Twitter , Drug Administration , Instagram , Youtube , Ministry Of Health , Met High , Met Intermediate , Colorado Cancer Center , Principal Investigator , Breakthrough Therapy Designation , Innovation Passport , Allergan Aesthetics , Private Securities Litigation Reform Act , Quarterly Reports , Overexpressing Non Small Cell Lung Cancer , Across Clinical Trial Samples , Real World Patient Cohorts From , Hope National Medical , Cancer Conference , Non Small Cell Lung Cancer , Agents Targeting , Onco Targets , Abbvie ,